前列地尔在慢性阻塞性肺疾病合并慢性肺心病患者治疗中的应用效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Prostaglandin(PGE1)on pulmonary arterial pressure and pulmonary function in patients with chronic obstructive pulmonary disease(COPD)complicated with chronic cor pulmonale.Methods From May 2016 to October 2017,62 patients with COPD complicated with chronic cor pulmonale in our hospital were randomly divided into two groups,31cases in each group.The control group was received routine treatment and the study group was treated with Alprostadil.The clinical effect of two groups was observed and analyzed.Results Before treatment,FEV1/FVC and FEV1of two groups were no significant differences between forced expiratory volume of one second,forced vital capacity,forced expiratory volume of one second and pulmonary arterial pressure(P＞0.05).After treatment,FEV1/FVC and FEV1were all expected higher in the study group,the pulmonary arterial pressure was lower than that in the control group(P＜0.05).There was no significant difference in pulmonary capillary permeability between the two groups before treatment(P＞0.05),and after treatment,pulmonary capillary permeability was better in the study group than in the control group(P＜0.05).Before treatment,there was no significant difference between the two groups in the partial pressure of oxygen(PaO2)and the oxygenation index[P(A-A)O2](P＞0.05).After treatment,PaO2was higher in the study group than that in the control group,P(A-a)O2was lower than that in the control group,the differences were statistically significant （P＜0.05）.Conclusion The application of Alprostadil in COPD patients with chronic pulmonary heart disease can achieve the exact effect and improve the pulmonary function.

Key words： Alprostadil Chronic obstructive pulmonary disease Chronic pulmonary heart disease Pulmonary arterial pressure Pulmonary function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YI Xiao-li
	LI Shi-xiong
	ZHEN New-xian

Cite this article:

YI Xiao-li,LI Shi-xiong,ZHEN New-xian. Application effect of Alprostadil in the treatment of patients with chronic obstructive pulmonary disease and chronic cor pulmonale[J]. 中国当代医药, 2018, 25(9): 53-55.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I9/53

[1]	王莉，汤燕，巨安丽.丹参川芎嗪注射液联合前列地尔注射液治疗慢性肺源性心脏病急性加重期的临床疗效分析[J].实用心脑肺血管病杂志，2015，23（9）：108-110.
[2]	张波.慢性阻塞性肺疾病合并肺心病15例临床治疗分析[J].中国伤残医学，2015，23（18）：99-100，101.
[3]	刘顺林，王桂月前列地尔对慢性阻塞性肺疾病相关肺动脉高压的疗效观察[J].现代实用医学，2016，28（1）：15-16.
[4]	王方宁.前列地尔联合辛伐他汀治疗慢性阻塞性肺疾病合并慢性肺心病急性加重期40例临床观察[J].中国实用医药，2015，20（26）：129-130.
[5]	吕宏勋.前列地尔对慢性阻塞性肺疾病急性加重期患者肺动脉高压的影响[J].临床研究，2016，24（1）：102.
[6]	胡振宇，邹外龙.前列地尔辅治慢性阻塞性肺疾病患者疗效及对血液流变学、肺动脉压、血气指标、IL-8、TNF-α和CRP 的影响[J].疑难病杂志，2015，14（6）：572-574.
[7]	丁万建.前列地尔治疗慢性阻塞性肺疾病合并肺动脉高压疗效观察[J].医药，2017，9（1）：00229.
[8]	翟梅，王小卫，薛华.前列地尔注射液对高原地区慢性阻塞性肺疾病相关肺动脉高压患者的影响[J].中西医结合心脑血管病杂志，2017，15（19）：2501-2503.
[9]	严建新.对慢性肺心病急性期患者使用前列地尔注射液进行治疗的效果分析[J].当代医药论丛，2015，15（22）：184-186.
[10]	张红，张在芬，岳妍秋.前列地尔联合无创正压通气在慢性阻塞性肺疾病急性加重期合并肺心病患者中的应用观察[J].国际医药卫生导报，2016，22（7）：934-937.
[11]	荣宁，尹行志，谢秀兰，等.丹红注射液联合前列地尔治疗慢性阻塞性肺疾病伴肺源性心脏病并心力衰竭患者的临床疗效[J].实用心脑肺血管病杂志，2017，15（3）：83-87.
[12]	邓军.前列地尔联合丹参酮ⅡA治疗肺动脉高压患者的临床效果评价[J].现代诊断与治疗，2017，28（4）：654-655.
[13]	李占欣，王立石，李栋，等.血必净联合前列地尔治疗慢性阻塞性肺疾病并发多器官功能障碍综合征的疗效研究[J].医学综述，2016，22（1）：184-185.
[14]	张月琴.前列地尔联合丹参多酚酸盐治疗慢性血栓栓塞性肺动脉高压的疗效观察[J].中国中西医结合杂志，2015，35（2）：250-251.
[15]	周巨彬.前列地尔对慢性肺源性心脏病肺动脉高压疗效的临床研究[J].中国医药科学，2017，7（3）：100-102.